In the evolving healthcare landscape, India’s pharmaceutical industry stands tall as a beacon of innovation, affordability, and scale. Rightly referred to as the “pharmacy of the world,” the sector contributes more than 20% of the global supply of generic medicines, and 60% of vaccines, to over 150 countries. The COVID-19 pandemic reinforced India’s leadership, as pharma companies ensured uninterrupted access to essential medicines. However, this defining moment also prompted scrutiny of the industry’s environmental impact, from excessive water use to waste discharge and emissions.
Sudarshan Jain, Secretary General, Indian Pharmaceutical Alliance (IPA), emphasizes that India’s pharmaceutical industry is increasingly embracing sustainability as a core operational +, with a strong focus on ESG performance.
This article was originally published in Pharma Bio World
